Equities Analysts Offer Predictions for CRSP Q1 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for CRISPR Therapeutics in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.35) for the quarter, down from their previous estimate of ($1.25). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at ($5.58) EPS and FY2026 earnings at ($5.50) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

A number of other brokerages have also recently commented on CRSP. Citigroup dropped their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday, February 18th. Morgan Stanley upped their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Friday, March 21st. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a report on Wednesday, February 12th. Finally, Chardan Capital reduced their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Stock Down 0.0 %

Shares of NASDAQ:CRSP opened at $37.77 on Friday. The firm has a fifty day simple moving average of $40.97 and a two-hundred day simple moving average of $43.81. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $67.88. The stock has a market capitalization of $3.24 billion, a P/E ratio of -8.64 and a beta of 1.85.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after acquiring an additional 35,196 shares during the period. Sanctuary Advisors LLC grew its position in CRISPR Therapeutics by 17.8% during the third quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company’s stock valued at $398,000 after buying an additional 1,258 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics in the third quarter worth about $40,000. Franklin Resources Inc. grew its position in shares of CRISPR Therapeutics by 12.7% during the 3rd quarter. Franklin Resources Inc. now owns 7,097 shares of the company’s stock valued at $339,000 after acquiring an additional 800 shares during the period. Finally, Nordea Investment Management AB increased its stake in shares of CRISPR Therapeutics by 4.4% in the 4th quarter. Nordea Investment Management AB now owns 125,400 shares of the company’s stock valued at $4,913,000 after purchasing an additional 5,300 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares of the company’s stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.